Latest Peplin news

news

09-June-09

Peplin Initiates Phase 3 Clinical Trials with PEP005 Gel in AK on Face and Scalp read more

28-May-09

Peplin's Positive Phase II AK Trial Results Published in JAAD read more

17-May-09

Positive Results for Peplin's First Phase III AK Trial read more

15-May-09

Peplin Results for the Quarter Ended 31 March 2009 read more

›› More News

Cheri Jones

Vice President, Regulatory Affairs

Ms. Jones has served as our Vice President, Regulatory Affairs since June 2006. Previously, from February 2003 to February 2006, Ms. Jones served as Vice President Regulatory Affairs at QLT U.S.A., Inc., a biopharmaceutical company. Prior to working at QLT U.S.A., Inc., Ms. Jones worked for Obagi Medical Products, Inc., a publicly-held pharmaceutical company, Valeant Pharmaceuticals International, a publicly-held pharmaceutical company, Alpharma Inc., a publicly-held pharmaceutical company, and Bristol-Myers Squibb Company, a publicly-held pharmaceutical company.

Ms. Jones received a B.S. in health care administration and an M.S. in pharmaceutical marketing from St. John's University, College of Pharmacy.  Cheri has been designated a Fellow of the Regulatory Affairs Professional Society (FRAPS) and is Regulatory Affairs Certified.

Executive Management